Toll-like receptor 4 decoy, TOY, attenuates Gram-negative bacterial sepsis

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Jung, Keehoon ^a   Lee, Jung Eun ^a   Kim, Hak Zoo ^a   Kim, Ho Min ^a   Park, Beom Seok ^a   Hwang, Seong Ik ^a   Lee, Jie Oh ^a   Kim, Sun Chang ^a   Koh, Gou Young ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4 DECOY; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; RECOMBINANT PROTEIN; TLR4 DECOY; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENETIC ANALYSIS; GLYCOSYLATION; LIFESPAN; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SEPSIS; THROMBOGENESIS; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CHEMISTRY; GRAM NEGATIVE BACTERIUM; HUMAN; METABOLISM; MICROBIOLOGY; PROTEIN TERTIARY STRUCTURE;

BACTERIA (MICROORGANISMS); HAGFISH; MUS; NEGIBACTERIA;

ANIMALS; CYTOKINES; EXTRACELLULAR MATRIX; GRAM-NEGATIVE BACTERIA; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 70350540674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007403     Document Type: Article

References (31)

1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
2. Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3: 169-176.
3. Tobias PS, Soldau K, Ulevitch RJ (1986) Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 164: 777-793.
4. Wright K (1990) Bad news bacteria. Science 249: 22-24.
5. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777-1782.
6. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN (2001) MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 276: 38044-38051.
7. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
8. Barton GM, Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300: 1524-1525.
9. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19: 24-32.
10. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, et al. (2002) Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3: 667-672.
11. Miyake K (2003) Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 3: 119-128.
12. Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT (2006) Md-2. Immunobiology 211: 437-447.
13. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
14. Kim HM, Park BS, Kim JI, Kim SE, Lee J, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
15. Bella J, Hindle KL, McEwan PA, Lovell SC (2008) The leucine-rich repeat structure. Cell Mol Life Sci 65: 2307-2333.
16. Pugin J, Stern-Voeffray S, Daubeuf B, Matthay MA, Elson G, et al. (2004) Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 104: 4071-4079.
17. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT (2005) Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 175: 6465-6472.
18. Ohto U, Fukase K, Miyake K, Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316: 1632-1634.
19. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
20. Hyakushima N, Mitsuzawa H, Nishitani C, Sano H, Kuronuma K, et al. (2004) Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol 173: 6949-6954.
21. Kim HM, Oh SC, Lim KJ, Kasamatsu J, Heo JY, et al. (2007) Structural diversity of the hagfish variable lymphocyte receptors. J Biol Chem 282: 6726-6732.
22. Rossignol DP, Lynn M (2005) TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs 6: 496-502.
23. Hwang SJ, Choi HH, Kim KT, Hong HJ, Koh GY, et al. (2005) Expression and purification of recombinant human angiopoietin-2 produced in Chinese hamster ovary cells. Protein Expr Purif 39: 175-183.
24. Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112: 460-467.
25. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R (2002) In vivo imaging of NF-kappa B activity. J Immunol 168: 1441-1446.
26. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, et al. (2009) Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A 106: 2348-2352.
27. Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, et al. (2007) TLR4/ MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 179: 6107-6114.
28. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, et al. (2005) A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 174: 6416-6423.
29. Wu X, Qian G, Zhao Y, Xu D (2005) LBP inhibitory peptide reduces endotoxin-induced macrophage activation and mortality. Inflamm Res 54: 451-457.
30. Tasaka S, Ishizaka A, Yamada W, Shimizu M, Koh H, et al. (2003) Effect of CD14 blockade on endotoxin-induced acute lung injury in mice. Am J Respir Cell Mol Biol 29: 252-258.
31. Kang S, Lee SP, Kim KE, Kim HZ, Memet S, et al. (2009) Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages. Blood 113: 2605-2613.